Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs

Strand, Vibeke; de Vlam, Kurt; Covarrubias-Cobos, Jose A; Mease, Philip J; Gladman, Dafna D; Graham, Daniela; Wang, Cunshan; Cappelleri, Joseph C; Hendrikx, Thijs; Hsu, Ming-Ann

期刊名称RMD Open
作者Strand, Vibeke; de Vlam, Kurt; Covarrubias-Cobos, Jose A; Mease, Philip J; Gladman, Dafna D; Graham, Daniela; Wang, Cunshan; Cappelleri, Joseph C; Hendrikx, Thijs; Hsu, Ming-Ann
卷第5卷
期第1期
电子ISSN2056-5933
文件大小2427.06KB
发表时间2019-01
DOI10.1136/rmdopen-2018-000806

发现好书期刊，享受阅读乐趣

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs